Paolo Tarantino: How do the results of DESTINY-Breast06 change our practice?

Paolo Tarantino shared on LinkedIn:

“How do the results of DESTINY-Breast06 change our practice?

Should T-DXd be used to treat HER2-ultralow metastatic breast cancer?

How should T-DXd now be sequenced with other therapies, such as oral chemotherapy or other antibody-drug conjugates?

At Dana-Farber Cancer Institute we routinely conduct internal polls on practice-changing data to produce Consensus Guidelines. All of these consensus are publicly available on our website.

Read the T-DXd Consensus document here.”

Source: Paolo Tarantino/LinkedIn

More posts featuring Paolo Tarantino on oncodaily.com

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a  publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.